Research ArticleSynthesis of nanodiamond–daunorubicin conjugates to overcome multidrug chemoresistance in leukemia
Graphical Abstract
An artistic rendering of ND-R conjugates approaching a cancer cell. ND particles (green) consist of green spheres representing carbon atoms, while DNR molecules, consisting of teal (carbon), blue (nitrogen), gray (hydrogen), red (oxygen) spheres, are attached to the surface of the ND. When resistance develops in cancer, drug efflux can become a serious issue by removing intracellular therapeutics, as shown by blue arrow depicting the efflux of DNR by efflux pumps (yellow). However, ND-enabled delivery has demonstrated the potential to overcome drug efflux and improve treatment outcome, as shown by the ND-mediated DNR entering the nucleus of the cancer cell.
Section snippets
ND-R loading and optimization
To form ND-R conjugates, DNR was reversibly loaded onto ND platforms. ND and DNR were mixed at various ratios (w/w), followed by adjusting pH to basic conditions to promote binding. After incubation (5 min, 25 °C), the solution was centrifuged (15 min, 2500 rpm, ~ 1450 g) to pellet bound ND-R. Unbound DNR remained in the supernatant and was subsequently removed. This supernatant was used to quantify unbound DNR to calculate the amount of DNR bound. The pelleted ND-R was resuspended in water using
Results
The ND platform was engineered to form a delivery system capable of combating resistant leukemia by shuttling DNR. Requisite of effective delivery vehicles, NDs have demonstrated outstanding biocompatibility.33, 34, 35 Figure 1, B shows the biocompatibility of varying ND concentrations exposed to K562 cells. Remarkably, cells exhibited > 90% viability after exposure to 0.0005-0.5 mg/ml NDs, compared with < 5% viability for positive control (SDS 1%). ND platforms also possess robust binding
Discussion
Cancer therapies can fail due to increases in activity of cellular efflux mechanisms. Higher levels of chemotherapeutic efflux lead to reductions in intracellular drug concentration and subsequent progression of drug insensitivity.9 The three most prominent MDR transporters typically attributed to chemotherapeutic efflux, are ABCB1 (MDR1, P-glycoprotein), ABCC2 (MRP1), and ABCG2 (BCRP, MXR). Overexpression of these transporters has also been correlated with more aggressive phenotypes of cancer
References (51)
- et al.
Multidrug resistance gene (mdr1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia
Blood
(2008) - et al.
Cd33 expression and p-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy
Blood
(2007) - et al.
Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles
J Control Release
(2003) - et al.
Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance
Cancer Lett
(2002) - et al.
Biodistribution and fate of nanodiamonds in vivo
Diamond Relat Mater
(2009) - et al.
Covalent immobilization of DNA on diamond and its verification by diffuse reflectance infrared spectroscopy
Chem Phys Lett
(2002) - et al.
Nanodiamond–insulin complexes as ph-dependent protein delivery vehicles
Biomaterials
(2009) - et al.
Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia
Blood
(1991) - et al.
Consequences of strong and diverse electrostatic potential fields on the surface of detonation nanodiamond particles
Diamond Relat Mater
(2009) - et al.
Identification, quantification and modification of detonation nanodiamond functional groups
Diamond Relat Mater
(2012)
Expression and activity of breast cancer resistance protein (bcrp) in de novo and relapsed acute myeloid leukemia
Blood
Nanoparticles for drug delivery: the need for precision in reporting particle size parameters
Eur J Pharm Biopharm
Cancer statistics, 2011
CA: A Cancer Journal for Clinicians
Acute myeloid leukemia
N Engl J Med
Novel mechanisms of drug resistance in leukemia
Leukemia
Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group
J Clin Oncol
The role of drug efflux pumps in acute myeloid leukemia
Leuk Lymphoma
Concomitant abcg2 overexpression and flt3-itd mutation identify a subset of acute myeloid leukemia patients at high risk of relapse
Cancer
Abc transporters in cancer: more than just drug efflux pumps
Nat Rev Cancer
Anticancer multidrug resistance mediated by mrp1: recent advances in the discovery of reversal agents
Med Res Rev
Nanoparticle therapeutics: an emerging treatment modality for cancer
Nat Rev Drug Discov
Cancer nanotechnology: opportunities and challenges
Nat Rev Cancer
Beyond the sparkle: the impact of nanodiamonds as biolabeling and therapeutic agents
ACS Nano
Cited by (77)
Introduction to nanotechnological utility in the pharmaceutical industry
2023, Nanotechnology for Drug Delivery and PharmaceuticalsDiamond particles aggregation in aqueous electrolytes with multivalent ions
2022, Diamond and Related MaterialsNanopolymeric systems to improve brain cancer treatment outcomes
2021, Advances and Challenges in Pharmaceutical Technology: Materials, Process Development and Drug Delivery StrategiesNanodiamonds with powerful ability for drug delivery and biomedical applications: Recent updates on in vivo study and patents
2020, Journal of Pharmaceutical AnalysisCitation Excerpt :Cell line studies on a K562 human myelogenous leukemia cell line with multidrug resistance and augmented daunorubicin exposure was carried out for efficacy enhancement demonstration. NDs enhanced the daunorubicin delivery to resistant cells [71]. NDs are used as a drug carrier mainly in any of the forms viz. NDs assemble on a chemical substrate to form a thin film, having interactions with a drug in two dimensions (forming spontaneous clusters also named as NDs hydrogel with low free energy in an aqueous solution), having interactions with a drug in three dimensions [16].
Nanodiamonds: Minuscule gems that ferry antineoplastic drugs to resistant tumors
2019, International Journal of Pharmaceutics
D.H. is a co-author of a patent application associated with nanodiamond drug delivery.
No conflict of interest was reported by the other authors of this paper.
D.H. gratefully acknowledges support from the National Science Foundation CAREER Award (CMMI-0846323), Center for Scalable and Integrated NanoManufacturing (DMI-0327077), CMMI-0856492, DMR-1105060, V Foundation for Cancer Research Scholars Award, Wallace H. Coulter Foundation Translational Research Award, Society for Laboratory Automation and Screening (SLAS) Endowed Fellowship, Beckman Coulter, National Cancer Institute grant U54CA151880 (The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health), and European Commission funding program FP7-KBBE-2009-3. E.K.C. gratefully acknowledges support from the Cancer Science Institute of Singapore (RCE CSI Main Grant) and Ministry of Education Academic Research Fund-Tier 1 grant R-184-000-227-112. H.B.M. gratefully acknowledges support from the Northwestern University Mechanical Engineering Department for the Walter P. Murphy fellowship, terminal year Cabell fellowship, and Predictive Science and Engineering Design (PSED) fellowship. This research used resources of the QUEST cluster at Northwestern University and the Argonne Leadership Computing Facility at Argonne National Laboratory, which is supported by the Office of Science of the U.S. Department of Energy under contract DE-AC02-06CH11357.